| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -16.7 | -15.8 |
| EPS (diluted, $ a share) | $-0.31 | $-0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TENX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tenax Therapeutics, Inc.: key numbers
- Share price
- $1.48Close, Nov 16
- Market cap
- $67.4M
- Shares outstanding
- 45.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tenax Therapeutics, Inc.
All →Tenax Therapeutics Insider ADAR1 Capital Management LLC Buys $1.46M of Stock
ADAR1 Capital Management LLC bought 922,849 shares of Tenax Therapeutics, Inc. at $1.51 to $1.66 a share (average $1.59) in 3 transactions, worth $1.46M in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 7,447,000 (+4.7%).
- Value
- $1.46M
- Shares
- 922,849
- Average price
- $1.59
- Holding change
- +4.7%
- Trade date
- Oct 19, 2026 to Oct 21, 2026
Tenax Therapeutics Investor Presentation
Tenax Therapeutics filed an updated investor presentation detailing strategic changes to its Phase 3 LEVEL-2 clinical trial for TNX-103 in PH-HFpEF. The company is pausing enrollment to amend protocol criteria based on findings from its completed LEVEL trial and has requested a Type C meeting with the FDA to discuss the development path.